Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorCHU de Quebec-Universite Laval
About this trial
Bispecific antibody therapies targeting BCMA (B-cell maturation antigen) represent a novel therapeutic approach for patients with multiple myeloma. They are currently used in cases of refractory multiple myeloma but are also being investigated in earlier lines of treatment. However, these new therapies can lead to deeper immunosuppression and exacerbate an underlying immunosuppressive state in patients with multiple myeloma. As a result, infectious complications are common with these therapies and are a significant concern. Therefore, preventing infections in this population is crucial. However, data on the best strategies for prevention are currently lacking.
Eligibility criteria
Qualifiers
≥ 18 years old
≥ 1 prior lines of therapy
Receiving a BCMA-directed T-cell Engager therapy (starting on treatment)
On previous Ig support or not
Disqualifiers
Less than 18 years old
Pregancy or breastfeeding
Trial design
Treatments tested in this trial
- Target trough IgG level of 8-10 g/L
- Target trough IgG level 4-6 g/L
- No history of recurrent or severe infections and total IgG level higher or equal at 4 g/L
Treatment groups
80 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov